S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
Log in

Crispr Therapeutics Price Target & Analyst Ratings (NASDAQ:CRSP)

$53.58
+2.67 (+5.24 %)
(As of 11/12/2019 04:00 PM ET)
Today's Range
$51.26
Now: $53.58
$56.16
50-Day Range
$35.64
MA: $42.75
$54.75
52-Week Range
$22.22
Now: $53.58
$56.16
Volume1.63 million shs
Average Volume619,595 shs
Market Capitalization$2.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.15

Analyst Ratings

Crispr Therapeutics (NASDAQ:CRSP) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
14 Wall Street analysts have issued ratings and price targets for Crispr Therapeutics in the last 12 months. Their average twelve-month price target is $58.25, suggesting that the stock has a possible upside of 8.72%. The high price target for CRSP is $72.50 and the low price target for CRSP is $21.00. There are currently 1 sell rating, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.712.672.532.36
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $58.25$57.56$58.30$48.92
Price Target Upside: 8.72% upside13.54% upside15.01% upside21.71% upside

Crispr Therapeutics (NASDAQ:CRSP) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Crispr Therapeutics (NASDAQ:CRSP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2019OppenheimerUpgradeMarket Perform ➝ Outperform$65.00High
10/21/2019Chardan CapitalSet Price TargetBuy$72.50Low
10/21/2019Piper Jaffray CompaniesReiterated RatingOverweightHigh
8/1/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$64.00Low
7/31/2019Needham & Company LLCReiterated RatingBuy$62.00Low
7/30/2019Roth CapitalBoost Price Target$50.00 ➝ $65.00Medium
7/30/2019BarclaysBoost Price TargetOverweight$59.00 ➝ $62.00Medium
7/30/2019BTIG ResearchBoost Price TargetBuy ➝ Positive$51.00 ➝ $59.00Medium
7/30/2019William BlairReiterated RatingHoldMedium
7/26/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$72.00High
4/11/2019Evercore ISIInitiated CoverageOutperformLow
1/28/2019Goldman Sachs GroupDowngradeBuy ➝ Neutral$78.00 ➝ $40.00Low
1/22/2019CitigroupDowngradeNeutral ➝ Sell$28.00 ➝ $21.00High
12/31/2018SunTrust BanksReiterated RatingBuyMedium
10/10/2018Wells Fargo & CoInitiated CoverageOutperform ➝ Outperform$65.00High
10/9/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
9/20/2018Raymond JamesInitiated CoverageUnderperform ➝ UnderperformHigh
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$69.00High
(Data available from 11/12/2017 forward)
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel